Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | TBXAS1 | P24557 | 13/20 | 0.34 |
| ▸ | FLT1 | P17948 | 1/20 | 0.33 |
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | PTGIS | Q16647 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | PRKCI | P41743 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10831208 | 0.72 | CDK2 (0.42) | CYP11B2SRC | |
| SCHEMBL3540598 | 0.68 | CYP11B2 (0.65) | CYP11B2TBXAS1CDK8CDK9LIMK1 | |
| SCHEMBL10830618 | 0.67 | RAB9A (0.47) | PTGS2CYP1A2 | |
| SCHEMBL3534128 | 0.67 | CYP11B2 (1.00) | CYP11B2TBXAS1IDO1 | |
| Hydrochloric Acid SCHEMBL3535788 | 0.67 | CYP11B2 (0.63) | CYP11B2TBXAS1CDK8CDK9LIMK1 | |
| SCHEMBL25652325 | 0.67 | CYP11B2 (0.48) | CYP11B2TBXAS1PTGS1PTGS2PTGIS | |
| SCHEMBL21323991 | 0.67 | CYP11B2 (0.55) | CYP11B2TBXAS1 | |
| Hydrochloric Acid SCHEMBL3539978 | 0.66 | CYP11B2 (0.97) | CYP11B2TBXAS1IDO1 | |
| SCHEMBL9261340 | 0.65 | CYP11B2 (0.60) | CYP11B2TBXAS1IDO1 | |
| SCHEMBL3536508 | 0.64 | CYP11B2 (0.55) | CYP11B2SRCTBXAS1CDK8CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10166214-B2 | Somatostatin receptor subtype 4 (SSTR4) agonists | CENTREXION THERAPEUTICS CORPORATION (US) | 2019-01-01 | — | — | US | disclosed |
| US-20180092880-A1 | SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180092880-A1 | SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | SSTR4, SSTR3, SSTR1 | CYP11B2 2088/4885SRC 3001/4885TBXAS1 830/4885 |
| US-10166214-B2 | Somatostatin receptor subtype 4 (SSTR4) agonists | SSTR4, SSTR3, SSTR1 | CYP11B2 2088/4885SRC 3001/4885TBXAS1 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.